Select country set
Menu Shopping cart 0,00 Search
Distributed product

MiRXES Fortitude Kit 2.1, COVID-19 Real Time RT-PCR Test

  • Regulatory status:RUO
  • Type:RT-qPCR
  • Other names:COVID-19, nCoV, Wuhan Coronavirus
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price

New 4480002 200 tests (kit)
PubMed Product Details
Technical Data




  • MiRXES Fortitude Kit 2.1, an in-vitro diagnostics (IVD) test kit, contains assays and controls for the qualitative detection of SARS-CoV-2 specific RNA, via an one-step, multiplex real-time RT-PCR reaction that involves,
    Reverse transcription of purified sample RNA into cDNA
    PCR amplification of two SARS-CoV-2 target sequences and the Internal Control
    Simultaneous detection of the PCR amplicons by fluorescent dye labelled probes
  • The MiRXES Fortitude Kit 2.1 contains three unique sets of forward primers, reverse primers and probes, pre-mixed in Primers-Probes Mix 2.1 (Kit Component 6)
    ORF1ab region 1 (probe with FAM fluorophore) of SARS-CoV-2 genome
    ORF1ab region 2 (probe with HEX fluorophore) of SARS-CoV-2 genome
    Internal Control (probe with Cy5 fluorophore)
  • The MiRXES Fortitude Kit 2.1 also contains three different controls
    Internal Control (Kit Component 1), containing template targeted by the Internal Control assay
    Positive Control 2.1 (Kit Component 2), containing SARS-CoV-2 genome regions targeted by both FAM labelled and HEX labelled SARS-CoV-2 assays
    Negative Control (Kit Component 3)
  • Each MiRXES Fortitude Kit 2.1 contains the following 7 components in 10 vials. Each kit is sufficient for 200 reactions.


COVID-19, Nasopharyngeal swabs


-25°C to -15°C, Protect from light



  • For research use only
  • Kit includes Internal Control template, Positive Control and Negative Control

Research topic



The MiRXES Fortitude Kit 2.1 contains the assays and controls, based on real-time Reverse Transcriptase-Polymerase Chain Reaction workflow, for the qualitative detection of SARS-CoV-2 specific RNA in nasopharyngeal swab samples. MiRXES Fortitude Kit 2.1 is intended for use by qualified clinical laboratory personnel trained in the techniques of molecular biology, real-time RT-PCR and in vitro diagnostic procedures.
A positive result from the test indicates the presence of SARS-CoV-2 specific RNA in the test sample; correlation with patient history, clinical symptoms and other diagnostic or epidemiological information may be necessary to determine the infection status.
A negative result does not preclude SARS-CoV-2 infection and should not be used as the sole basis for patient management decisions.

Related Products Docs